Summary
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
